Crosslinking of α-synuclein by advanced glycation endproducts — an early pathophysiological step in Lewy body formation?

Braak, H., Braak, E., Yilmazer, D., Schultz, C., Devos, R. A., I., Jansen, E. N. H., 1995. Nigral and extranigral pathology in Parkinson's disease. J. Neural. Transm., Suppl., 15–31.

Castellani, 1996, Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease, Brain Res., 737, 195, 10.1016/0006-8993(96)00729-9

Castellani, 2000, Sequestration of iron by Lewy bodies in Parkinson's disease, Acta Neuropathol. (Berl), 100, 111, 10.1007/s004010050001

Gomez-Tortosa, 2000, Alpha-Synuclein immunoreactivity in dementia with Lewy bodies: morphological staging and comparison with ubiquitin immunostaining, Acta Neuropathol. (Berl.), 99, 352, 10.1007/s004010051135

Jenner, 1998, Understanding cell death in Parkinson's disease, Ann. Neurol., 44, S72, 10.1002/ana.410440712

Khalifah, 1999, Amadorins: novel post-Amadori inhibitors of advanced glycation reactions, Biochem. Biophys. Res. Commun., 257, 251, 10.1006/bbrc.1999.0371

Krüger, 2000, Involvement of alpha-synuclein in Parkinson's disease and other neurodegenerative disorders, J. Neural. Transm., 107, 31, 10.1007/s007020050002

Loske, C., Gerdemann, A., Schepl, W., Wycislo, M., Schinzel, R., Palm, D., Riederer, P., Münch, G., 2000. Transition metal mediated glycoxidation accelerates crosslinking of β-amyloid peptide. Eur. J. Biochem., 1–9.

Mogi, 1994, Interleukin-1-beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from Parkinsonian patients, Neurosci. Lett., 180, 147, 10.1016/0304-3940(94)90508-8

Mogi, 1994, Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from Parkinsonian patients, Neurosci. Lett., 165, 208, 10.1016/0304-3940(94)90746-3

Mullarkey, 1990, Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes, Biochem. Blophys. Res. Commun., 173, 932, 10.1016/S0006-291X(05)80875-7

Münch, 1998, Advanced glycation end products in neurodegeneration-more than early markers of oxidative stress, Ann. Neurol., 44, S 85, 10.1002/ana.410440713

Münch, 1998, Advanced glycation endproducts are associated with Hirano bodies in Alzheimer's disease, Brain Res., 796, 307, 10.1016/S0006-8993(98)00328-X

Münch, 1998, Alzheimer's disease-synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts, J. Neural. Transm., 105, 439, 10.1007/s007020050069

Münch, 1994, The cognition-enhancing drug tenilsetam is an inhibitor of protein crosslinking by advanced glycosylation, J. Neural. Transm.-PD Dementia Sect., 8, 193, 10.1007/BF02260940

Münch, 1997, Advanced glycation endproducts in ageing and Alzheimer's disease, Brain Res. Rev., 23, 134, 10.1016/S0165-0173(96)00016-1

Neumann, 1999, High molecular weight hyaluronic acid inhibits advanced glycation endproduct-induced NF-kappa B activation and cytokine expression, FEBS Lett., 453, 283, 10.1016/S0014-5793(99)00731-0

Pearce, 1997, Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease, J. Neural. Transm., 104, 661, 10.1007/BF01291884

Qian, 1998, Transition metals bind to glycated proteins forming redox active glycochelates-implications for the pathogenesis of certain diabetic complications, Biochem. Biophys. Res. Commun., 250, 385, 10.1006/bbrc.1998.9326

Sian, 1999, Parkinson's disease: a major hypokinetic basal ganglia disorder, J. Neural. Transm., 106, 443, 10.1007/s007020050171

Smith, 1996, Early contribution of oxidative glycation of Alzheimer's disease, Neurosci. Lett., 217, 210, 10.1016/0304-3940(96)13100-1

Spillantini, 1998, Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies, Proc. Natl. Acad. Sci. USA., 95, 6469, 10.1073/pnas.95.11.6469

Thornalley, P. J., 1998. Glutathione-dependent detoxification of alpha-oxoaldehydes by the glyoxalase system: involvement in disease mechanisms and antiproliferative activity of glyoxalase I inhibitors. Chem. Biol. Interact., 111–112, 137–151.

Weber, 1998, Distribution of advanced glycation end products in the cerebellar neurons of dogs, Brain Res., 791, 11, 10.1016/S0006-8993(97)01421-2

Yan, 1994, Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors binding proteins, J. Biol. Chem., 269, 9889, 10.1016/S0021-9258(17)36966-1

Youdim, 1997, Understanding Parkinson's disease, Sci. Am., 276, 52, 10.1038/scientificamerican0197-52